... of breast cancer. This study aimed to investigate whether PPI use interferes with the efficacy of CDK4/6 inhibitors. Methods: This retrospective, multicenter, real-world study included 205 patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Patient data were collected from...

... inhibitors (ICIs). Pembrolizumab has been approved for the use of breast cancer, but its relationship with BMI on survival outcomes is unclear. Methods: We conducted a retrospective, propensity score-matched cohort study using the TriNetX Analytics Network database, which contains de-identified data from...

... the feasibility of applying the ACOSOG Z0011 criteria to Japanese patients with early-stage breast cancer (median follow-up, 3 years). Their results over the longer term can now be presented. Risk factors for axillary and locoregional recurrence in Z0011-eligible patients are unknown. Methods: Long-term survival...

...Luděk Záveský; Eva Jandáková; Vit Weinberger; Luboš Minář; Milada Kohoutová; Adela Tefr Faridová; Ondřej Slanař Introduction: Breast cancer comprises the leading cause of cancer-related death in women. MicroRNAs (miRNAs) have emerged as important factors with concern to carcinogenesis and have...

... consequence, a tier-based filtration led by AI-driven predictors and scoring system was implemented to the overall decision-making process, resulting in a list of prioritised genes. Methods: The study has been conducted on breast cancer patients of homogeneous ethnicity. Germline rare variants have been...

...Luděk Záveský; Eva Jandáková; Vít Weinberger; Luboš Minář; Milada Kohoutová; Ondřej Slanař Introduction: Breast cancer is the most common cancer and the leading cause of cancer death in women. Recent research indicates that human endogenous retroviruses (HERVs) may be linked to carcinogenesis...

...−) progressive metastatic breast cancer (MBC). The SOLAR-1 trial demonstrated the efficacy of this oral agent and showed that, while alpelisib improves outcomes compared to placebo, it is also associated with clinically relevant adverse events (AEs). There is a pressing need for improved knowledge...

... or metastatic breast cancer or metastatic gastric cancer. Safety outcomes were adverse events (AEs) and adverse drug reactions. Effectiveness outcomes were tumor response and event-free survival. Results: 424 patients were evaluated: 366 patients (86%) with early breast cancer, 53 patients (13%) with metastatic...

...Yaning He; Qi Chen; Fangyuan Zhu; Chaojun Liu; Yingbo Shao; Hui Liu Introduction: Radiotherapy (RT) plays an indispensable role in postoperative breast cancer treatment. This study aimed to assess the feasibility of preoperative RT for stage III breast cancer by comparing preoperative RT...

... subtype of breast cancer. However, this molecular type requires more effective treatment regimens in the neoadjuvant therapy stage. Methods: This study enrolled breast cancer patients who were treated at Harbin Medical University Cancer Hospital with neoadjuvant treatment between October 2011 and May 2019...

...Langfeier Liu; Nicholas Lewis; Weihong Sun; Junmin Whiting; Susan Hoover; Ricardo L.B. Costa Introduction: T1a/b, node-negative (node − ), triple-negative breast cancers (TNBCs) are underrepresented in randomized drug-approving clinical trials. Given their low incidence, the clinicopathological...

...Yu Yang; Chang Liu; Zhong-Ling Zhuo; Fei Xie; Ke Wang; Shu Wang; Xiao-Tao Zhao Introduction: BRCA1/2 germline mutations are the most well-known genetic determinants for breast cancer. However, the distribution of germline mutations in non-BRCA1/2 cancer susceptibility genes in Chinese breast cancer...

...Izzet Dogan; Inci Kizildag; Selnur Özkurt; Kamuran Ibis; Sezai Vatansever; Pinar Saip; Adnan Aydiner Introduction: Patients with HER2-positive metastatic breast cancer are at risk for developing brain metastases. Different anti-HER2 treatments can be used in the management of the disease...

... with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer after NAC. Methods: We evaluated 417 patients who were diagnosed with invasive breast cancer and treated with NAC followed by curative surgery between January 2007 and December 2020 and analyzed...

...Vivien Nguyen; Juliana Chen; Reginald Lord; Veronica Preda Introduction: Weight gain during chemotherapy for breast cancer is a well-documented adverse effect. The purpose of this study was to investigate how multidisciplinary weight management involving endocrinology, dietitian, and exercise...

... for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC) setting. We investigated whether anthracycline can be omitted in HER2-positive early breast cancer patients receiving neoadjuvant taxane plus...

... reaction of bisphosphonates and denosumab, and Actinomyces spp. as well. In this study, we evaluated the abundance of Actinomyces spp. in breast cancer patients undergoing chemotherapy compared to healthy controls. Methods: Oropharyngeal samples were collected from treatment-naive early-stage breast cancer...

...Kei Yamaguchi; Ryoichi Matsunuma; Ryosuke Hayami; Michiko Tsuneizumi Introduction: Not only the 21-gene recurrence score (RS) assay but also online prognostic tools and immunohistochemical prognostic models predict chemotherapy benefits for women with early breast cancer (BC). Multigene assays...

...Orly Yariv; Raz Mutai; Ofer Rotem; Daliah Tsoref; Yasmin Korzets; Assaf Moore; Tzippy Shochat; Rinat Yerushalmi; Hadar Goldvaser Introduction: The impact of exogenous estrogen exposure on breast cancer characteristics and outcomes is not well described. We aimed to investigate the effect of prior...

... with early-stage, hormone-positive (HR+) breast cancer (BC), with higher scores predicting greater risk of recurrence and benefit from chemotherapy. Patients with ODx RS >25 typically recieve adjuvant chemotherapy; however, data regarding efficacy of chemotherapy for reducing recurrence in this population...